| INVITED REVIEW |
|
| Year : 2023 | Volume
: 2
| Issue : 1 | Page : 13-19 |
|
|
Combining metabolic surgery with medications for type 2 diabetes: Is there a benefit?
Alexis Sudlow1, Dimitri J Pournaras2, Carel W le Roux3
1 Department of Bariatric Surgery, Southmead Hospital, Bristol, UK; Department of Experimental Pathology, University College Dublin, Dublin, Ireland
2 Department of Bariatric Surgery, Southmead Hospital, Bristol, UK
3 Department of Experimental Pathology, University College Dublin, Dublin, Ireland
Correspondence Address:
Dr. Carel W le Roux
Department of Experimental Pathology, University College Dublin, Dublin
Ireland
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jbs.jbs_16_22
|
|
|
Bariatric surgery has been consistently demonstrated in randomized controlled trials to be the most effective treatment currently available for patients with Type 2 diabetes mellitus (T2DM) and obesity. In spite of this, with the emergence of longer-term data, it is now becoming apparent that some of the metabolic benefits afforded by bariatric surgery fatigue with time, prompting clinicians to re-consider how patients should be managed in the postoperative period. As is seen with many other chronic diseases including peripheral vascular disease as well as some cancers, surgery is seen as a means of inducing disease control with medications being employed to maintain sustained remission. In recent years, there have been remarkable advances in pharmacotherapy for the treatment of T2DM as well as additional agents which can produce clinically significant weight loss. Having recognized the potential need for further treatment following bariatric surgery along with the availability of highly effective medical therapies presents the opportunity to explore a multimodal approach to care, combining medications with surgery to potentially improve long-term outcomes.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
